Entering text into the input field will update the search result below

InMed Pharma pivots to single-agent cannabinoid for rare skin disorder; shares up 2%

Mar. 13, 2019 11:42 AM ETInMed Pharmaceuticals Inc. (INM) StockBy: Douglas W. House, SA News Editor3 Comments
  • Citing a greater likelihood of success, InMed Pharmaceuticals (OTCQX:IMLFF +2.3%) has dropped its two-cannabinoid combo, INM-750, in favor of a single cannabinoid approach, designated as INM-755, for the potential treatment of epidermolysis bullosa, a rare inherited skin disorder characterized by blisters and erosions from minor injury, rubbing or scratching.
  • A Phase 1 study should launch by year-end.

Recommended For You

About INM Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
INM--
InMed Pharmaceuticals Inc.